Despite Lower Earnings Than Three Years Ago, KPC PharmaceuticalsInc (SHSE:600422) Investors Are up 155% Since Then
Despite Lower Earnings Than Three Years Ago, KPC PharmaceuticalsInc (SHSE:600422) Investors Are up 155% Since Then
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But when you pick a company that is really flourishing, you can make more than 100%. For example, the KPC Pharmaceuticals,Inc (SHSE:600422) share price has soared 141% in the last three years. That sort of return is as solid as granite. On top of that, the share price is up 12% in about a quarter. But this move may well have been assisted by the reasonably buoyant market (up 11% in 90 days).
在買入公司股票(假設沒有槓桿作用)之後,最糟糕的結果是你損失了所有投入的錢。但是,當你選擇一家真正蓬勃發展的公司時,你可以 使 超過 100%。例如,KPC Pharmicals, Inc (SHSE: 600422) 的股價在過去三年中飆升了141%。這種回報就像花崗岩一樣堅實。最重要的是,股價在大約一個季度內上漲了12%。但是,這一舉措很可能得到了相當活躍的市場(90天內上漲了11%)的推動。
While the stock has fallen 4.1% this week, it's worth focusing on the longer term and seeing if the stocks historical returns have been driven by the underlying fundamentals.
儘管該股本週下跌了4.1%,但值得關注長期來看,看看股票的歷史回報是否是由基礎基本面推動的。
While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.
雖然市場是一種強大的定價機制,但股價反映了投資者的情緒,而不僅僅是潛在的業務表現。通過比較每股收益(EPS)和一段時間內的股價變化,我們可以了解投資者對公司的態度是如何隨着時間的推移而變化的。
During the three years of share price growth, KPC PharmaceuticalsInc actually saw its earnings per share (EPS) drop 8.2% per year.
在股價增長的三年中,KPC PharmaceuticalsInc的每股收益(EPS)實際上每年下降8.2%。
This means it's unlikely the market is judging the company based on earnings growth. Given this situation, it makes sense to look at other metrics too.
這意味着市場不太可能根據收益增長來評判該公司。鑑於這種情況,考慮其他指標也是有意義的。
Languishing at just 0.9%, we doubt the dividend is doing much to prop up the share price. You can only imagine how long term shareholders feel about the declining revenue trend (slipping at 3.1% per year). What's clear is that historic earnings and revenue aren't matching up with the share price action, very well. So you might have to dig deeper to get a grasp of the situation
股息僅爲0.9%,我們懷疑股息是否能在支撐股價方面起到多大作用。你只能想象長期股東對收入下降趨勢(每年下滑3.1%)的看法。顯而易見的是,歷史收益和收入與股價走勢不符。因此,你可能需要更深入地挖掘才能了解情況
You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).
您可以在下面看到收入和收入如何隨着時間的推移而變化(點擊圖片了解確切的值)。
![earnings-and-revenue-growth](https://newsfile.futunn.com/public/NN-PersistNewsContentImage/7781/20240514/0-3bcf97b140b8c7e4303e6de574c9389a-0-df5c22fd6bc42f54878a894827462099.png/big)
If you are thinking of buying or selling KPC PharmaceuticalsInc stock, you should check out this FREE detailed report on its balance sheet.
如果你想買入或賣出KPC PharmaceuticalsInc的股票,你應該查看這份關於其資產負債表的免費詳細報告。
What About Dividends?
分紅呢?
It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of KPC PharmaceuticalsInc, it has a TSR of 155% for the last 3 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence!
重要的是要考慮任何給定股票的股東總回報率和股價回報率。股東總回報率是一種回報計算方法,它考慮了現金分紅的價值(假設收到的任何股息都經過再投資)以及任何貼現資本籌集和分拆的計算價值。可以公平地說,股東總回報率爲支付股息的股票提供了更完整的畫面。就KPC PharmaceicalsInc而言,其股東回報率在過去三年中爲155%。這超過了我們之前提到的其股價回報率。而且,猜測股息支付在很大程度上解釋了這種分歧是沒有好處的!
A Different Perspective
不同的視角
We're pleased to report that KPC PharmaceuticalsInc shareholders have received a total shareholder return of 8.5% over one year. Of course, that includes the dividend. However, that falls short of the 19% TSR per annum it has made for shareholders, each year, over five years. The pessimistic view would be that be that the stock has its best days behind it, but on the other hand the price might simply be moderating while the business itself continues to execute. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 1 warning sign for KPC PharmaceuticalsInc you should be aware of.
我們很高興地向大家報告,KPC PharmaceuticalsInc的股東在一年內獲得了8.5%的股東總回報率。當然,這包括股息。但是,這低於其在五年內每年爲股東創造的19%的股東總回報率。悲觀的看法是,該股已經過了最好的時機,但另一方面,在業務本身繼續執行的同時,價格可能只是在放緩。儘管市場狀況可能對股價產生的不同影響值得考慮,但還有其他因素更爲重要。一個很好的例子:我們發現了你應該注意的KPC PharmaceicalsInc的1個警告信號。
If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).
如果你想與管理層一起購買股票,那麼你可能會喜歡這份免費的公司名單。(提示:業內人士一直在購買它們)。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。
譯文內容由第三人軟體翻譯。